NR,
Did you have a chance to talk to anyone in management about these questions,..?
Resverlogix didn't provide much, if any, new info in the Biotech Showcase slides. Unless Noretreat or someone else who attended Biotech Showcase is able to share any updates, we are stuck in the waiting game based upon guidance from 4 months ago. AGM 9/12/2018 they announced they were at 200 MACE events with MACE events occuring at 10-15 per month and that the target was still 250. We'll be 4 months post AGM tomorrow. So based on that 4 month old guidance, we would project that 240-260 MACE events have occurred by now.
Now that JP Morgan/Biotech Showcase week in San Francisco has ended and everyone is getting back to their normal routines, here are some questions to ponder for the next month.
Is that MACE rate range still accurate or has it been less than 10 per month over the past 4 months?
Are they planning to make an announcement once 250 events have been reached and dosing has ended?
What market conditions or catalysts is Resverlogix waiting for to pursue the US listing?
Since it is pretty clear that top-line data won't be coming before January 31, 2019, how will Resverlogix deal with the Third Eye loan requirement that Growacet reminding us of last month?
Will there be an end of January surprise with Resverlogix/BETonMACE getting a late breaking clinical trial slot at the March ACC 2019 meeting?
Is there a planned BETonMACE rationale and design publication in advance of top-line data?
Will we hear anything out of Resverlogix prior to BIO CEO & Investor Conference February 11-12, 2019 in New York?
Since BETonMACE has been fully enrolled for several months now, certain aspects of the original trial design changed and since BETonMACE ClinicalTrials.gov hasn't been updated since September of 2017, when will Resverlogix get their act together and update the status of the ClinicalTrials.gov site? Are they leaving the door open for performing an interim analysis and opening enrollment back up?
BearDownAZ
